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Abstract
In HIV-1 infected patients, increase of liver enzymes may be mainly due to viral coinfections, alcohol intake,
hepatotoxic drugs or autoimmune diseases. Three cases of aminotransferase elevation occurred during a phase of
uncontrolled viral replication combined with a severe immunodeficiency and resolved by an effective HAART are
described, focusing on the etio-pathogenetic role possibly played by HIV-1 infection.
Background
Human immunodeficiency virus type-1 (HIV-1) infec-
tion is commonly characterized by the presence of a
progressive depletion of CD4
+ T lymphocytes, associated
with the occurrence of opportunistic infections and can-
cers. Abnormal liver enzymes (aspartate aminotransfer-
ase, AST and alanine aminotransferase, ALT) are
frequently seen in HIV-1 infected patients and may be
due to a variety of factors, such as coinfection with
hepatotropic viruses, i.e. hepatitis B (HBV) and C
(HCV) viruses, Cytomegalovirus (CMV) and Epstein-
Barr virus (EBV), opportunistic infections, cancers, auto-
immune hepatitis (AIH), alcohol abuse, and exposure to
hepatotoxic drugs, including highly active antiretroviral
therapy (HAART). Identification and management of
these factors is often difficult because of the coexistence
of multiple causes [1-4].
We report three cases of HIV-1 infected patients with
advanced immunodeficiency (CD4
+ T lymphocytes less
than 200/cu.mm.) showing severe aminotransferase ele-
vations (defined as ≥ 5× the upper limit of normal
values) occurred during a period of uncontrolled viral
replication, and in the absence of any other apparent
cause of liver disease. AST and ALT values returned
within the normal ranges in a few months after the
onset of an effective HAART.
Case Presentation
Case 1
On January 1987, a 30-years-old man who have sex with
men (MSM) was found to be HIV-1 positive (CDC A2)
for a history of unprotected sexual intercourses. On
September 1990 the patient has presented a CMV reti-
nitis and a zidovudine-based antiretroviral therapy was
started. From 1990 to 2002 he switched several antire-
troviral treatments, due to side effects or development
of drug resistance. During this period a partial immune
recovery was observed and plasma HIV-RNA levels
sometimes reached undetectable values, with liver func-
tion tests (LFTs) always within the normal ranges. On
October 2003, increased levels of AST (135 UI/l) and
ALT (89 UI/l) were present. Moreover, the patient
showed a failure of the lopinavir/ritonavir-based therapy
(HIV-RNA 32.000 copies/ml; CD4
+ T lymphocytes
95 cells/cu.mm.). Not excluding a drug toxicity, HAART
was discontinued and the patient underwent to a com-
plete assessment of hepatic functions, including HAV,
HBV and HCV antibodies, HBV-DNA, HCV-RNA,
EBV-DNA and CMV-DNA, all resulted negative. A
genetic test for hemochromatosis and the research of
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or other metabolic disorders, with the exception of a
mild increase in triglycerides, were present. A liver
ultrasound showed hepatomegaly without parenchymal
abnormalities. A liver biopsy revealed hepatosteatosis
with multifocal lymphocytic lobular infiltrates. From
August 2004 to August 2006, despite the presence of a
multi-drug resistant virus, antiretroviral therapy was
reintroduced, with the intent to delay the clinical evolu-
tion of HIV-1 disease (Table 1). During these years an
immune-virological worsening (CD4
+ T lymphocytes
36 cells/cu.mm.; HIV-RNA 223.805 copies/ml) and a
deterioration of AST and ALT values (400 UI/l and
600 UI/l respectively) were observed. On August 2006, a
darunavir/ritonavir + enfuvirtide + tenofovir and lami-
vudine/zidovudine fixed-dose regimen was started, based
on the results of a genotypic resistance test (GRT) and
the availability of new drugs. After one month, HIV-
RNA levels decreased to 100 copies/ml and AST and
ALT values returned below 50 UI/ml. Three months
later, plasma HIV-RNA was undetectable whereas LFTs
reached normal levels. After one year, enfuvirtide was
replaced with raltegravir, and lamivudine/zidovudine
fixed-dose + tenofovir discontinued. Plasma viral load
has remained on undetectable levels and CD4
+ Tl y m -
phocytes have now reached 430 cells/cu.mm., with LFTs
always within the normal ranges (Figure 1).
Case 2
A 31-years-old man on September 1995 was found to be
HIV-1 positive during a hospitalization caused by Pneu-
mocystis jiroveci pneumonia (CDC C3). He started anti-
retroviral therapy on November 1995 with zidovudine
and didanosine, when his CD4
+ Tc e l lc o u n tw a s
32 cells/cu.mm. He reported a history of unprotected
heterosexual intercourses. Up to September 2006, he
switched several treatments for side effects or for the
occurrence of drug resistance (Table 1), caused by a low
level of adherence to the prescribed therapies. Despite
this, the patient showed an immune recovery with CD4
+
T cells increased up to 600/cu.mm: his LFTs were pre-
dominantly within the normal ranges, with only small
increases due to occasional alcohol intake. On Septem-
ber 2006, during a rescue treatment with atazanavir/
ritonavir, lamivudine and tenofovir, the patients experi-
enced a new virologic failure (HIV-RNA 150.803 copies/
ml) with a worse in CD4
+ Tc e l lc o u n t( 5 5c e l l s / c u .
mm.) and an increase of LFTs (ALT 119 UI/l and AST
270 UI/l). No diabetes or other metabolic disorders
were present. Antiretrovirals were discontinued and the
patient underwent to laboratory and instrumental exam-
inations to investigate the aetiology of the liver disease:
HBV, HCV, CMV and EBV antibodies, and the relative
DNA or RNA detections by polymerase chain reaction
(PCR), were negative as well as the auto-antibody titres.
A liver ultrasound showed only a mild hepatomegaly,
whereas a liver biopsy revealed mild hepatosteatosis
without fibrosis, and focal lymphocytic lobular infil-
trates. The patient remained without antiretroviral ther-
apy until October 2007, when, despite the persistence of
abnormal LFTs, the treatment was restarted with a dar-
unavir/ritonavir + enfuvirtide + raltegravir-based
HAART, taking in account the results of a new GRT.
After only one month of therapy, LFTs returned within
the normal ranges and two months later plasma HIV-
RNA values reached undetectable levels (Figure 1), both
in association with a sustained immune recovery (CD4
+
T lymphocytes raised from 15 to 211 cells/cu.mm.).
Actually the patient is taking a simplified regimen with
darunavir/ritonavir + raltegravir, his CD4
+ T cells have
reached 359/cu.mm., with plasma HIV RNA always
below the limits of detection and LFTs within the nor-
mal ranges.
Case 3
The third patient is a 47-years-old MSM, HIV-1 positive
from December 1997, when the research of anti-HIV-1
antibodies was performed for the onset of disseminated
Kaposi’s sarcoma (KS) lesions with visceral involvement
(CDC C3). HAART with indinavir, lamivudine and sta-
vudine was started, shortly allowing an immune-virolo-
gical recovery. After three months of therapy, CD4
+
T lymphocytes raised from 155 to 461 cells/cu.mm. and
plasma HIV RNA decreased from 251.000 copies/ml to
undetectable levels. KS lesions disappeared and an ame-
lioration of clinical conditions was observed. Up to
April 2006, he continued HAART, switching from indi-
navir to nevirapine for simplification, and from stavu-
dine to tenofovir for the onset of peripheral neuropathy.
During this period plasma HIV RNA remained unde-
tectable and CD4
+ T lymphocytes were constantly over
500 cells/cu.mm. LFTs were always within the normal
ranges or showed little abnormalities, clearly referred to
the use of specific antiretroviral drugs (hyperbilirubine-
mia and gamma-glutamil-transpeptidase mild increases
with indinavir and nevirapine, respectively). HBV and
HCV serology were negative, whereas anti-CMV and
anti-EBV IgG antibodies were present. From April 2006
the patient was no longer subjected to clinical and
laboratory scheduled follow-up. He discontinued
HAART for the onset of lipodistrophy signs, and on July
2009 he returned to our clinic, showing a worsening of
clinical conditions (fever, weight loss, night sweats, and
oropharyngeal candidiasis). Laboratory tests revealed:
HIV-RNA 153.465 copies/ml, CD4
+ T lymphocytes 222
cells/cu.mm., ALT 131 UI/l and AST 282 UI/l. HBV
and HCV serology remained negative as well as the rela-
tive DNA and RNA by PCR analysis; a liver ultrasound
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research for AIH was negative. After the results of a
resistance test, a new antiretroviral combination based
on raltegravir plus tenofovir/emtricitabine fixed-dose
was prescribed. A rapid amelioration of the clinical con-
ditions was observed and after one month of therapy he
showed an immune-virological recovery with a persis-
tently improvement of LFTs (Figure 1).
Conclusions
Involvement of the liver during the course of HIV-1 dis-
ease may result from viral or other infections, or being
Table 1 Therapeutic history of the patients
Antiretroviral drugs Period of therapy Reasons for change
Case 1
ZDV 1990 -1993
ddI May 1993 - Oct 1993 diarrhoea
ddC Dec 1993 - Jan 1995
ZDV, 3TC Feb 1995 - Jul 1995
ZDV, 3TC, SQV Aug 1995 - Feb 1996 diarrhoea
IDV, 3TC, ZDV Mar 1996 - Apr 1998 kidney stones
d4T, EFV, NFV May 1998 - Apr 1999 psichiatric disorders
ZDV, 3TC, ABC, IDV/r May 1999 - Jan 2000 cutaneous reaction
ZDV, 3TC, IDV/SQV/r Feb 2000 - Sep 2000 virologic failure
ddI, d4T, NVP, LPV/r Oct 2000 cutaneous reaction
ddI, d4T, EFV, LPV/r Nov 2000 - Oct 2001
ddI, d4T, LPV/r Nov 2001 - Oct 2003 virologic failure and LFTs increase
3TC, TDF, EFV Aug 2004 - Jun 2005 failure
fAPV/r, SQV Jul 2005 cutaneous reaction
SQV/r, EFV Aug 2005 - Oct 2005 cutaneous reaction
LPV/r, SQV Oct 2005 - Dec 2005 itching and diarrhoea
LPV/r, 3TC, TDF Dec 2005 - Jun2006 failure
DRV/r, ENF, TDF, ZDV/3TC Aug 2006 - Aug 2007
DRV/r, RAL, TDF, ZDV/3TC Aug 2007 - Aug 2008 simplification
DRV/r, RAL Aug 2008 - ongoing simplification
Case 2
ZDV, ddI Nov 1995 - Aug 1996
ZDV, ddC Sep 1996 - Dec 1996
ZDV, ddC, IDV Dec 1996 - May 1997
ZDV, 3TC, IDV Jun 1997 - Nov 1998 kidney stones
NFV, d4T, NVP Dec 1998 - Mar 2000 abdominal pain and diarrhea
ZDV/3TC, SQV/r Mar 2000 - Apr 2000 anemia
d4T, 3TC, SQV/r May 2000 - Mar 2005 lack of adherence and resistance development
LPV/r, 3TC, TDF Apr 2005 - Oct 2005 virologic failure
ATV/r, 3TC, TDF Oct 2005 - Sep 2006 virologic failure and LFTs increase
DRV/r, ENF, RAL Oct 2007 - Feb 2008
DRV/r, RAL Feb 2008 - ongoing simplification
Case 3
IDV, 3TC, d4T Dec 1997 - Mar 2002
NVP, 3TC, d4T Apr 2002 - May 2004 simplification
NVP, 3TC, TDF Jun 2004 - Apr 2006 peripheral neuropathy, lipoatrophy
RAL, TDF/FTC Aug 2009 - ongoing
Note: GRT, genotypic resistance test; ZDV, zidovudine; ddI, didanosine; ddC, zalcitabine; 3TC, lamivudine; SQV, saquinavir; IDV, indinavir; d4T, stavudine; EFV,
efavirenz; NFV, nelfinavir; ABC, abacavir; NVP, nevirapine; LPV, lopinavir; TDF, tenofovir difumarate; fAPV, fosamprenavir; DRV, darunavir; ENF, enfuvirtide; RAL,
raltegravir; ATV, atazanavir; FTC, emtricitabine; r = ritonavir booster.
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patients described here showed an advanced HIV-1 dis-
ease with an unexpected increase of LFTs occurred in
the presence of a severe immunodeficiency (CD4
+
T cells < 200/cu.mm.) and a high level of viral replica-
tion, due to drug failure or voluntary HAART disconti-
nuation. All patients showed plasma HIV RNA values
> 100.000 copies/ml and the absence of other possible
causes of liver injury, such as hepatotropic virus infec-
tions, hepatotoxic drugs administration, alcohol intake
and/or other substances’ abuse, or cancers. Furthermore,
the search for other pathogens (i.e., typical or atypical
mycobacterial infection, Treponema pallidum infection)
resulted negative. Hepatic biopsy performed in two sub-
jects was not of diagnostic value. A triggering role in
t h ea m i n o t r a n s f e r a s ei n c r e a s ep l a y e db ya n t i r e t r o v i r a l
drugs (i.e. LPV/r and ATZ/r) at least in the first two
subjects could not be excluded, being hepatotoxicity of
these drugs frequently reported [5-7]. In all subjects
LFTs rapidly returned within the normal ranges, as soon
as the control of viral replication has been achieved; this
was observed in association with an immune recovery,
suggesting the hypothesis of ap a t h o g e n e t i cr o l ep l a y e d
by HIV-1 infection in the liver damage. In patients with
HIV-1 disease there are a few data on liver injury not
related to hepatotropic viruses or hepatotoxic drugs
[8-10]. An acute liver disease without the identification
of a distinct pathogen can complicate the clinical evolu-
tion of HIV-1 infection in children [11]. Only a few
cases of AIH, in which a role of HIV-1 as a causative
agent was hypothesized, have been described [12,13].
Viral infections may play a triggering role in the activa-
tion of auto-reactive T cells that attack hepatocytes
either for a molecular mimicry between viral and self-
antigens or by the modifications of self-antigens; alter-
natively, HIV-1 may cause a superantigen stimulation of
a subset of T cells responsible for the liver damage [13].
However, in our patients the detection of auto-antibodies
was negative, although their absence does not allow us
to absolutely exclude the diagnosis of AIH, and the
liver biopsy was not diagnostic. Hepatosteatosis was a
common autopsy finding in HIV/AIDS patients, exten-
sively described in the pre-HAART era [8]. In the
LFTs increase observed, a role of steatosis, whose
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Figure 1 Trend of HIV-1 RNA and ALT/AST levels. Aminotransferase (AST and ALT) values and plasma HIV-RNA levels in the three patients
before and after the beginning of an effective HAART. Normalization of both indexes after the start of the new combination therapy.
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performed in two patients, could not be excluded.
However, in our series the aminotransferase increase
has promptly resolved after the start of an effective
HAART, without interventions finalized to reduce
hepatosteatosis. Indeed, as previously reported [14],
such approaches lead to an improvement of antiretro-
viral drug tolerability only in coinfected patients.
In conclusion, in HIV-1 infected patients presenting
with an acute onset of abnormal LFTs, after the exclu-
sion of the most common causes of liver disease, it is
necessary to assess the effectiveness of the current
HAART and strongly evaluate the opportunity of start-
ing an alternative antiretroviral regimen, in the suspicion
of a HIV-1 induced hepatic disease.
Consent
Written informed consent was obtained from the
patients for publication of this case report and accompa-
nying images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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